AUS
NZ
UK
CA
USA
IND
ReNeuron Group plc (AIM:RENE), a UK-based leader in stem cell-derived exosome technologies, has provided an update on its ongoing administration process. The company, which entered administration on 20 March 2024, has been working with joint administrators Stephen Cork and Mark Smith of Cork Gully LLP to navigate its financial challenges.
Creditor Position
Since the appointment of the joint administrators, discussions have been ongoing with ReNeuron’s main creditors to clarify the company’s liabilities and assess its financial viability. There is currently a discrepancy between the amount the company can pay to settle its total liabilities and the claims sought by creditors.
Staff and Operations
In efforts to preserve value for creditors, the joint administrators have implemented cost rationalization measures. This includes redundancies among several employees and other cost-cutting initiatives. Despite these changes, key senior management members, including the Board of Directors and Randolph Corteling (Chief Scientific Officer), remain with the company to support the administration process.
Financing Discussions
ReNeuron, with assistance from its brokers, is seeking potential investors for a proposed fundraise. This new equity capital would enable the company to continue trading post-administration. However, completion of this proposed fundraise is contingent upon the company exiting administration with sufficient funds to settle all known creditors. Any new investment would be directed towards the company’s working capital needs for operations moving forward.
